Analysts’ Recent Ratings Changes for Reata Pharmaceuticals (RETA)

Reata Pharmaceuticals (NASDAQ: RETA) recently received a number of ratings updates from brokerages and research firms:

  • 5/9/2018 – Reata Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is engaged in identifying, developing and commercializing product candidates which modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress and inflammation to address the unmet medical needs of serious or life-threatening diseases. Reata Pharmaceuticals, Inc. is based in Irving, United States. “
  • 5/9/2018 – Reata Pharmaceuticals was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 5/3/2018 – Reata Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is engaged in identifying, developing and commercializing product candidates which modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress and inflammation to address the unmet medical needs of serious or life-threatening diseases. Reata Pharmaceuticals, Inc. is based in Irving, United States. “
  • 5/2/2018 – Reata Pharmaceuticals was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 5/2/2018 – Reata Pharmaceuticals was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 4/20/2018 – Reata Pharmaceuticals was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 4/9/2018 – Reata Pharmaceuticals had its “hold” rating reaffirmed by analysts at Cowen Inc.

Shares of Reata Pharmaceuticals opened at $32.13 on Friday, Marketbeat reports. The firm has a market capitalization of $801.62 million, a P/E ratio of -16.15 and a beta of 0.10. Reata Pharmaceuticals has a one year low of $30.62 and a one year high of $31.30. The company has a debt-to-equity ratio of -0.12, a current ratio of 2.62 and a quick ratio of 2.62.

Reata Pharmaceuticals (NASDAQ:RETA) last issued its earnings results on Tuesday, May 8th. The company reported $0.15 EPS for the quarter, topping the consensus estimate of ($0.61) by $0.76. The firm had revenue of $32.39 million during the quarter, compared to the consensus estimate of $10.21 million. sell-side analysts predict that Reata Pharmaceuticals will post -2.14 earnings per share for the current fiscal year.

A number of hedge funds have recently modified their holdings of RETA. MetLife Investment Advisors LLC bought a new position in Reata Pharmaceuticals in the fourth quarter worth $127,000. DekaBank Deutsche Girozentrale bought a new position in shares of Reata Pharmaceuticals during the first quarter valued at $152,000. Goldman Sachs Group Inc. bought a new position in shares of Reata Pharmaceuticals during the fourth quarter valued at $307,000. Virtus Fund Advisers LLC bought a new position in shares of Reata Pharmaceuticals during the fourth quarter valued at $394,000. Finally, UBS Group AG lifted its holdings in shares of Reata Pharmaceuticals by 473.6% during the first quarter. UBS Group AG now owns 19,933 shares of the company’s stock valued at $409,000 after acquiring an additional 16,458 shares during the period. 49.10% of the stock is owned by hedge funds and other institutional investors.

Reata Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases with therapies by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl for the treatment of patients with chronic kidney disease caused by Alport syndrome; and for a form of pulmonary arterial hypertension associated with connective tissue disease.

Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Mackay Shields LLC Acquires Shares of 30,300 LSC Communications
Mackay Shields LLC Acquires Shares of 30,300 LSC Communications
Mackay Shields LLC Invests $553,000 in Range Resources Corp.
Mackay Shields LLC Invests $553,000 in Range Resources Corp.
50,700 Shares in Immersion Co.  Purchased by Mackay Shields LLC
50,700 Shares in Immersion Co. Purchased by Mackay Shields LLC
SG Americas Securities LLC Takes $952,000 Position in Core-Mark Holding Company, Inc.
SG Americas Securities LLC Takes $952,000 Position in Core-Mark Holding Company, Inc.
Schlumberger Limited.  Position Boosted by Zeke Capital Advisors LLC
Schlumberger Limited. Position Boosted by Zeke Capital Advisors LLC
Aecon Group’s  “Outperform Overweight” Rating Reiterated at National Bank Financial
Aecon Group’s “Outperform Overweight” Rating Reiterated at National Bank Financial


Leave a Reply

 
© 2006-2018 Zolmax.